Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA33890 plus standard chemotherapy and bevacizumab versus placebo plus standard chemotherapy and bevacizumab in first-line metastatic microsatellite-stable colorectal cancer
NL-OMON61173Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Aug 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of INCA-33890 in colorectal cancer (CRC), sponsored by Incyte. Started Aug 2026; status: recruiting.
02
Drugs
INCA-33890
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON61173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61173.